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Abstract
Background: Smoking is an important risk factor for mental health-related problems. Numerous studies have
supported a bi-directional association between cigarette smoking and depression. Despite the advances in
understanding the comorbidity between both problems, the most effective psychological treatment that
simultaneously targets smoking and depressive symptomatology remains unclear. The objective of this study is to
assess the effectiveness of a cognitive-behavioral intervention for smoking cessation with components of behavioral
activation for managing depressed mood.
Method: A single blind, three-arm, superiority randomized controlled trial is proposed. Participants will be smokers
over 18 years old, who smoke at least 8 cigarettes per day. Participants will be randomized to one of three
conditions, using a 2:2:1 allocation ratio: 1) standard cognitive-behavioral smoking cessation treatment; 2) standard
cognitive-behavioral smoking cessation treatment plus behavioral activation; or 3) a three-month delayed treatment
control group. The primary outcome measures will be biochemically verified point-prevalence abstinence (carbon
monoxide in expired air) and significant change from baseline in depressive symptoms to the end of treatment,
and at the 3-, 6-, and 12-month follow-up.
Discussion: This study aims to assess the efficacy of a cognitive-behavioral intervention with behavioral activation
components for smoking cessation and depressive symptoms, compared to a standard cognitive-behavioral
intervention to quit smoking. As the relation between depressive symptoms, even at subclinical levels, and quitting
smoking difficulties is well known, we expect that such intervention will allow obtaining higher abstinence rates,
lower relapse rates, and mood improvement.
Trial registration: ClinicalTrials.gov: NCT02844595. Retrospectively registered 19th July, 2016. The study started in
January 2016, and the recruitment is ongoing.
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Background
Both smoking and depression are leading causes of disability,
mortality, and morbidity worldwide [1–3]. The frequent co-
occurrence of depression and smoking is well documented,
and empirical work suggests that smoking-depression
relations could be bi-directional [4, 5]. Epidemiological re-
search have shown that mood disorders are more prevalent
among smokers compared to nonsmokers from the general
population [6–8], and it has been found that smoking is also
associated with a greater risk of onset and persistence of
depression [9]. In addition, among treatment-seeking
smokers, several studies have found greater levels of mood
disorders, in both lifetime and past-year diagnoses [10].
Evidence suggests that smokers from the general
population with depressive symptoms or with a depressive
disorder, compared to those without one, present higher
levels of cigarette consumption, greater nicotine depend-
ence, are more likely to suffer intense nicotine withdrawal
symptoms and to fail when trying to quit smoking, have
more difficulties to maintain abstinence, and have a higher
risk of smoking relapse over time [5, 11–13]. Additionally,
it has been shown that even very low levels of pretreatment
depressive symptoms can impact smoking cessation treat-
ment outcomes [14].
At the same time, studies conducted both in general and
clinical populations have found that smoking cessation is
related to mood improvement in people who are able to
remain abstinent [15–17]. In a recent meta-analysis that
included 26 studies assessing mental health in persons with
and without psychiatric disorders, Taylor and colleagues
[18] found that quitting smoking is associated with a de-
crease in depressive and anxiety symptoms, with a reduc-
tion in stress levels, and an improvement in quality of life.
The U.S. Preventive Services Task Force (USPSTF) found
strong evidence that behavioral interventions substantially
improve achievement of tobacco cessation [19]. Despite this,
a reduction over time in abstinence rates has been shown
following psychological and/or pharmacological smoking
cessation treatment [20–22]. As recent studies suggest, this
trend could be due to a change in treatment-seeking
smokers, who show significantly greater self-reported de-
pressive symptoms when compared to prior studies [20, 23].
In relation to the efficacy of smoking cessation treatments
aimed at smokers with depression, Gierisch and colleagues
[24] conducted a systematic review and meta-analysis of
studies examining smoking cessation interventions for
smokers with past or current depression. Their results
showed a positive effect of adding a behavioral mood man-
agement component to smoking cessation intervention. Re-
cently, van der Meer and colleagues [25] reviewed 33 trials
that included smoking cessation interventions with specific
mood management components. Their results, in line with
previous ones, showed a significant positive effect of adding
psychosocial mood management components to a standard
smoking cessation intervention in smokers with current or
past depression.
Behavioral activation (BA) may be considered as a parsimo-
nious treatment option for depression, because it is less
complex but just as effective as cognitive-behavioral therapy
and anti-depressant medication [26, 27]. Moreover, Richards
and colleagues [28], who conducted the largest trial of BA for
depression to date, found that BA therapy is more time-
efficient and cost-effective when compared to cognitive-
behavioral treatment for depression, suggesting that BA
should be a front-line treatment for depression. It consists of
a structured intervention that uses the principles of operant
conditioning to activate clients to increase rewarding experi-
ences in their lives, the enjoyment of daily activities, and to
reconnect with environmental positive reinforcement [29].
The central role of reinforcement in the BA approach
makes this intervention a good option to be included in an
intervention to quit smoking. Audrain-McGovern and
colleagues [30] found that when depression-prone smokers
quit smoking, they experience the loss of smoking
reinforcement, a diminution in positive mood, a reduction
in the pleasure obtained from other rewarding experiences,
and an increase in negative affect. Their results also suggest
that a smoking lapse could reestablish these affective and
reward-related functions, resulting in a high probability of
smoking relapse.
In fact, BA integrated in smoking cessation interven-
tion has shown preliminary efficacy for depressive symp-
toms and improving smoking cessation outcomes among
adult smokers with depression. MacPherson and col-
leagues [31] carried out a pilot study [N = 68] examining
whether a behavioral activation treatment for smoking
cessation (BATS) could improve abstinence rates and de-
pressive symptoms compared to a standard smoking ces-
sation treatment. They found that the BATS group had
greater likelihood of point prevalence abstinence and
lower depressive symptoms at the end of the treatment
and at 6-month follow-up, compared with the standard
smoking cessation treatment group. Also, a recent case
series study [32] conducted with 3 inpatients (who partici-
pated in the open-label pilot phase of a larger ongoing
RCT) at a substance use treatment center, found that the
BA-Enhancing Smoking Cessation Program provides good
smoking cessation results and important decreases in
depressive symptoms.
Taken together, these previous findings suggest a potential
benefit of adding BA components to a smoking cessation
treatment. Through this intervention approach, exposure to
positive reinforcing alternatives to smoking cigarettes would
be increased, and the distress of the withdrawal syndrome
could be reduced, resulting in a possible improvement of
smoking abstinence rates and mood, even in smokers with
lower depressive symptoms. Due to the novelty of this
smoking cessation intervention, further research is needed
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with controlled trial designs, larger samples, and longer
follow-up periods.
Aims
The main aims of the present randomized controlled trial
are: 1) to assess the efficacy (smoking abstinence rates) of
a cognitive-behavioral smoking cessation treatment with
elements from behavioral activation for managing de-
pressed mood, compared with a standard smoking cessa-
tion treatment, at the end of treatment, and at 3-, 6-, and
12-month follow-ups; and 2) to assess whether the applied
cognitive-behavioral smoking cessation treatment plus
behavioral activation improves depressed mood, compared
with a standard smoking cessation treatment, at the end
of treatment and at 3-, 6-, and 12-month follow-ups.
Method
Study design
A three-arm, single blind superiority randomized con-
trolled design is proposed to assess the effectiveness of a
cognitive-behavioral intervention for smoking cessation
with components of BA. The overall study design is sum-
marized in Fig. 1.
Recruitment
Participants will be recruited through the media, posters in
healthcare centers, word of mouth, or they will be referred
to the unit by their primary care physician or other special-
ized services of the healthcare system. The different phases
of the study (assessment, treatment, and follow-ups) will be
carried out at the Smoking Cessation and Addictive
Disorders Unit of the University of Santiago de Compos-
tela, Galicia (Spain). Before participants enroll in the study,
informed consent for participation will be obtained.
Target population, blinding, randomization, and procedure
Sample selection will be carried out according to the
following inclusion criteria: aged 18 or over; wishing to
participate in the treatment program; providing written
informed consent; and smoking 8 or more cigarettes per
day. Exclusion criteria will be: a diagnosis of severe mental
disorder (bipolar disorder and/or psychotic disorder); con-
current substance use disorder (alcohol, cannabis, stimu-
lant, hallucinogen and/or opioid); having participated in the
same or similar treatment over the previous year or having
received pharmacological smoking cessation treatment
(nicotine replacement therapy, bupropion, or varenicline)
over the previous year; presence of a high life-risk path-
ology that would require immediate individual intervention
Fig. 1 Consort Diagram of Trial Progression
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(i.e., recent myocardial infarction); smoking tobacco prod-
ucts other than cigarettes (i.e., cigars); or failing to attend
the first treatment session.
Two baseline assessment sessions will be carried out
in a face-to-face interview. Researchers conducting such
assessments will be blind to group allocation, which will
occur subsequently. Due to the nature of the study, par-
ticipants will be aware that they will be assigned to one
of the three arms.
The randomization will be conducted according to a
computer generated allocation sequence (ratio: 2.2.1.): (1)
standard cognitive-behavioral smoking cessation treat-
ment; (2) standard cognitive-behavioral smoking cessation
treatment plus behavioral activation; or (3) a 3-month
delayed treatment control group. After that, both active
treatments will be administered in eight weekly 60-min
sessions.
At the end of treatment, there will be a post-treatment
assessment (during session 8) and face-to-face follow-
ups at 3, 6, and 12 months (Fig. 1). Self-reported abstin-
ence at the end of treatment and at the follow-ups will
be corroborated by measures of CO in expired air. In
those cases in which it is not possible to locate the par-
ticipants, they will be considered to be smokers, and at
the same level (in terms of tobacco-related variables) as
at the baseline assessment.
Sample size and power analysis
Previous studies of cognitive behavioral interventions for
smoking cessation [20, 33] and studies of cognitive behav-
ioral interventions for smoking cessation with compo-
nents targeting depressive symptoms [24, 31] suggest that
quit rates after treatment may range between 28% and
61.9%. The sample size for this study was calculated using
G*Power3 Software [34]. To detect a 20% difference be-
tween the two active groups in the proportion of individ-
uals with tobacco abstinence after treatment, with a power
of 80% and a significant p-value of 0.05, a total of 102
participants per active group will be required. The sample
size of the delayed-treatment control group will be 51 par-
ticipants. We have chosen an unbalanced design because
larger abstinence rates are expected in both active groups
as compared to the delayed-treatment control group.
Measures
Sociodemographic characteristics, smoking history, smok-
ing cessation treatment history, depression history, and
depression treatment history will be assessed using a face-
to-face structured interview. In addition, the following
instruments will be used (Table 1 lists the measures
collected at each time point):
– Smoking Habit Questionnaire [35], consisting of 56
items designed to gather information both on
sociodemographic variables (gender, age, marital
status, educational level) and tobacco use (i.e.,
number of cigarettes smoked per day).
– Fagerström Test for Cigarette Dependence (FTCD)
[36]. It is made up of six items for the assessment of
cigarette dependence. Scores ≥6 are considered to
be indicative of dependence [37]. Cronbach’s alpha
coefficient was.60 in studies conducted in Spain [38].
– Nicotine Dependence Syndrome Scale (NDSS) [39,
40]. Questionnaire based on multidimensional
conceptualization of substance dependence as a
syndrome. The reliability of the general factor that
evaluates nicotine dependence is good, Cronbach’s
alpha was.80.
– NicotineWithdrawal Scale Minnesota (MNWS) [41].
This is an 8-item scale measuring nicotine withdrawal
symptoms (depression, insomnia, irritability/frustra-
tion/anger, anxiety, difficulty concentrating, restlessness,
increased appetite/weight gain) and craving (desire or
urge to smoke, which is considered independently).
It is an instrument with good reliability, with a
Cronbach’s alpha was.85.
– Structured Clinical Interview, according to DSM-5
criteria for assessing tobacco use disorder.
– Screening Questionnaire Major Depressive Episode
(MDE) [42]. This is an instrument to detect past and
current major depressive episodes.
Table 1 Timeline for data collection across the trial
Measures Measurement time-point
Baseline End of
treatment
3-month
follow-up
6-month
follow-up
12-month
follow-up
Smoking Habit
Questionnaire
X
TUS, Tobacco
DSM-5 criteria
X
MDE X
UCLA X
RRS X
FTCD X X X X X
+NDSS X X X X X
MNWS X X X X X
BDI-II X X X X X
HRDS X X X X X
EROS X X X X X
BADS X X X X X
CO X X X X X
TUS Tobacco Use Disorder, MDE Screening Questionnaire Major Depressive
Episode; UCLA Loneliness Scale; RRS Ruminative Response Scale; FTCD
Fagerström Test of Cigarette Dependence; NDSS Nicotine Dependence
Syndrome Scale; MNWS Minnesota Nicotine Withdrawal Scale; BDI-II Beck
Depression Inventory II; HDRS Hamilton Depression Rating Scale; EROS
Environmental Reward Observation Scale; BADS Behavioral Activation for
Depression Scale; CO carbon monoxide in expired air
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– Beck Depression Inventory II (BDI-II) [43, 44]. This is a
21-item self-report scale measuring current depressive
symptoms. The internal consistency obtained in
Spanish sample with Cronbach’s alpha was.90.
– Hamilton Depression Rating Scale (HDRS) [45, 46].
This instrument was designed to quantitatively
assess the severity of depressive symptoms and to
monitor changes. The internal consistency obtained
with a Cronbach’s alpha was.72.
– The Environmental Reward Observation Scale
(EROS) [47, 48]. This is a brief self-report measure
designed to obtain efficient, reliable, and valid
information on the amount and availability of
environmental reward. The Spanish version has a
good internal consistency; Cronbach’s alpha was.86.
– Behavioral Activation for Depression Scale (BADS)
[49, 50]. This 25-item questionnaire was designed to
measure four basic dimensions of the behavioral
activation model: Activation, Avoidance/Rumination,
Work/School Impairment, and Social Impairment.
The scale shows good internal consistency with
Cronbach’s alpha was .90 for the total score, .81 for
the Activation subscale, .82 for the Avoidance/
Rumination subscale, .76 for the Work/School
Impairment subscale, and .88 for the Social
Impairment subscale.
– Ruminative Response Scale (RRS) [51, 52]. The RRS
is a 22-item self-report for assessing ruminative
coping responses to depressed mood. Treynor and
colleagues [53] found that 12 items from the RRS
overlapped with depressive symptoms, so that the
resulting 10-item version will be used. The RRS
Spanish version has been found to show adequate
psychometric properties with Cronbach’s alpha
scores for brooding and reflection of .73 and .72,
respectively
– UCLA Loneliness Scale (Version 3) [54, 55]. This is
a highly reliable instrument to measure loneliness,
with a Cronbach’s alpha was .94.
– Carbon monoxide in expired air assessment. We will
use the Micro + Smokerlyzer (Bedfont Scientific
Ltd., Maidstone, Kent, U.K.) to measure carbon
monoxide (CO) in expired air so as to corroborate
self-reported abstinence at the end of treatment and
at follow-ups, as suggested in previous studies [56].
Intervention conditions
Standard cognitive-behavioral smoking cessation treatment
The standard cognitive-behavioral smoking cessation
treatment is a manualized treatment for tobacco depend-
ence, called “Smoking Cessation Program” [57]. The
treatment components are: treatment contract, self-report
and graphic representation of cigarette consumption,
information about tobacco, nicotine fading [change of
cigarette brands each week, progressively decreasing the
intake of nicotine and tar), stimulus control, activities to
prevent withdrawal syndrome, physiological feedback (CO
in expired air) on cigarette consumption, and relapse-
prevention strategies (assertion training, problem-solving
training, changing tobacco-related misconceptions, man-
agement of anxiety and anger, exercise, weight control,
and self-reinforcing). Treatment will be delivered in eight
60-min sessions over 8 consecutive weeks.
Standard cognitive-behavioral smoking cessation treatment
and behavioral activation
Behavioral Activation will be applied along with the
previously described standard cognitive-behavioral smok-
ing cessation treatment. The treatment elements are the
above-mentioned ones plus the following: analysis of the
relationship between behavior and mood, identification of
situations and behaviors that decrease mood, identifying
avoidance behaviors, and identifying rumination and
worry, self-report of pleasant daily activities, pleasant
activity scheduling to increase engagement in rewarding
activities and to reduce patterns of behavioral avoidance.
Treatment will be delivered in eight 60-min sessions over
8 consecutive weeks.
Treatment delayed control group
It will be a delayed-treatment control group for a period of
3 months. After the 3-month period, another assessment
will be carried out, and then participants will be offered to
participate in a smoking cessation treatment (Table 2).
Therapist
Trained therapists (Master level in clinical or counseling
psychology) will conduct the assessment and intervention
sessions.
Treatment manual
Both treatments have been manualized with the aim of
training the therapist and improving the intervention
implementation. Both of them include a detailed session-
by-session protocol and follow-up procedures.
Intervention fidelity
All sessions will be video-recorded to supervise the ther-
apist and to assess intervention fidelity. Study supervi-
sors will assess fidelity through the random visualization
of treatment sessions in both active arms.
Outcomes
Primary outcome measures
– Point-prevalence abstinence defined according to
Russell Standard (RS) criteria [56]. Participants will
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Table 2 Summary of session-by-session outline of intervention procedures
Ss Cognitive-behavioral Smoking Cessation
Treatment (CBSCT)
CBSCT + Behavioral Activation
1 Overview of treatment
Smoking cessation treatment rationale
Review self-monitoring (tracking cigarettes and
smoking antecedents and consequences)
Indications about how to graphically represent
the No. of cigarettes/day
Reasons for smoking and for quitting
Discuss smoking history and quit experiences
Explain and provide written materials about
tobacco, nicotine dependence, smoking health
consequences and quit smoking benefits
Explain nicotine fading through brand change
Physiological feedback (CO)
As homework:
- Brand change
- Communicate to at least one person [family,
friend, coworker, etc.) that he/she is trying to quit
smoking in the next 30 days
- Not smoke more cigarettes than the average of
those smoked the previous week
- Leave a third of the cigarette without smoking
- Refuse cigarette offers
Overview of treatment
Smoking cessation treatment rationale
Review self-monitoring (tracking cigarettes and
smoking antecedents and consequences)
Indications about how to graphically represent
the No. of cigarettes/day
Reasons for smoking and for quitting
Discuss smoking history and quit experiences
Explain and provide written materials about
tobacco, nicotine dependence, smoking health
consequences and quit smoking benefits
Explain nicotine fading through brand change
Physiological feedback (CO)
As homework:
- Brand change
- Communicate to at least one person (family,
friend, coworker, etc.) that he/she is trying to quit
smoking in the next 30 days
- Not smoke more cigarettes than the average of
those smoked the previous week
- Leave a third of the cigarette without smoking
- Refuse cigarette offers
2 Check homework and nicotine fading
compliance
Continue smoking self-monitoring and analyze
smoking behavior during the week
Physiological feedback (CO)
Discuss brand change difficulties
New brand change and reduce No. of cigarettes
Review importance of social support
Introduce stimulus control technique to remove
situations conditioned to smoking
Nicotine withdrawal and strategies to avoid it
Breathing exercises and relaxation techniques
(practice as homework)
Check homework and nicotine fading
compliance
Continue smoking self-monitoring and analyze
smoking behavior during the week
Physiological feedback (CO)
Discuss brand change difficulties
New brand change and reduce No. of cigarettes
Review importance of social support
Introduce stimulus control technique to remove
situations conditioned to smoking
Nicotine withdrawal and strategies to avoid it
Breathing exercises and relaxation techniques
(practice as homework)
3 Check nicotine fading, cigarette reduction and
stimulus control compliance
Check breathing exercises compliance and
strategies to avoid withdrawal symptoms
Physiological feedback (CO)
Continue cigarette self-monitoring and analyze
smoking behavior
New brand change and reduce No. of cigarettes
Continue stimulus control technique
Explain and provide written materials for weight
control and exercise
Continue with breathing exercises and strategies
to avoid withdrawal symptoms
Check nicotine fading, cigarette reduction and
stimulus control compliance
Check breathing exercises compliance and
strategies to avoid withdrawal symptoms
Physiological feedback (CO)
Continue cigarette self-monitoring and analyze
smoking behavior
New brand change and reduce No. of cigarettes
Continue stimulus control technique
Explain and provide written materials for weight
control and exercise
Continue with breathing exercises compliance
and strategies to avoid withdrawal symptoms
Rationale of mood influence in smoking
cessation [provide written materials)
Homework: daily activities self-monitoring
4 Check nicotine fading, cigarette reduction and
stimulus control compliance
Check breathing exercises compliance and
strategies to avoid withdrawal symptoms
Physiological feedback (CO)
Continue smoking self-monitoring and analyze
smoking behavior
New brand change and reduction of No. of
cigarettes
Continue stimulus control technique
Stress and anxiety management strategies
Problem-solving training
Check nicotine fading, cigarette reduction and
stimulus control compliance
Check breathing exercises compliance and
strategies to avoid withdrawal symptoms
Physiological feedback (CO)
Continue smoking self-monitoring and analyze
smoking behavior
New brand change and reduction of No. of
cigarettes
Continue stimulus control technique
Stress and anxiety management strategies
Check activity scheduling and encourage
recognizing patterns of depressed behavior and
the way in which engaging in enjoyable and
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be considered abstinent if they report abstinence,
not even a puff of a cigarette, for ≥24 h at the end of
treatment, and for ≥7 days prior to follow-up day at
the 3-month follow-up, and have an expired carbon
monoxide reading of ≤10 ppm. At the 6- and 12-
month follow-ups, participants will be considered
abstinent if they report abstinence, not even a puff
of a cigarette, for ≥30 days prior to follow-up day,
and have an expired carbon monoxide reading of
≤10 ppm.
– Significant change in depressive symptoms on the
Beck Depression Inventory-II (BDI-II) from baseline
to the end of treatment, and at 3-, 6-, and 12-month
follow-up.
Table 2 Summary of session-by-session outline of intervention procedures (Continued)
important activities may impact their overall
mood
Homework: continue activity scheduling, create a
pleasant activities list and choose one to do
during the week
5 Check nicotine fading, cigarette reduction, and
stimulus control compliance
Physiological feedback (CO)
Continue smoking self-monitoring and analyze
smoking behavior
New brand change and reduction of No. of
cigarettes
Management of anxiety and anger
Self-reinforcing
Changing tobacco-related misconceptions
Check nicotine fading, cigarette reduction, and
stimulus control compliance
Check activity scheduling, pleasant activities list
elaboration, and pleasant activity compliance
Physiological feedback (CO)
Continue smoking self-monitoring and analyze
smoking behavior
New brand change and reduction of No. of
cigarettes
Management of anxiety and anger
Self-reinforcing
Changing tobacco-related misconceptions
Problem-solving training
Recognize avoidance behavior and impact on
mood
Activity scheduling and engagement in 2
pleasant activities/week
6 Quitting experience and withdrawal symptoms
Physiological feedback (CO)
Discuss and plan for high-risk lapse and relapse
situations
Motivating factors for maintaining abstinence
Benefits of quitting smoking
Common barriers for maintaining abstinence
Quitting experience and withdrawal symptoms
Physiological feedback (CO)
Discuss and plan for high-risk lapse and relapse
situations
Motivating factors for maintaining abstinence
Benefits of quitting smoking
Common barriers for maintaining abstinence
Ruminative thoughts, smoking cessation process,
and relapse
Check activity scheduling and pleasant activity
compliance
Activity scheduling for the next week and
engagement in 2 pleasant activities/week
7 Quitting experience and withdrawal symptoms
Physiological feedback (CO)
Discuss and plan for high-risk lapse and relapse
situations
Motivating factors for maintaining abstinence
Benefits of quitting smoking
Strategies for relapse prevention
Quitting experience and withdrawal symptoms
Physiological feedback (CO)
Discuss and plan for high-risk lapse and relapse
situations
Motivating factors for maintaining abstinence
Benefits of quitting smoking
Review how behavioral activation impacts their
overall mood
Review avoidance behavior and ruminative
thoughts’ significance
Strategies for relapse prevention
8 Physiological feedback (CO)
Managing the future as ex-smokers
Encouragement for abstinence maintenance
Support for lapses and relapse
Review motivating factors, lifestyle changes,
physical and cognitive-behavioral health
improvement
Treatment conclusion and management of
potential obstacles
Physiological feedback (CO)
Managing the future as ex-smokers
Encouragement for abstinence maintenance
Support for lapses and relapse
Review motivating factors, lifestyle changes,
physical and cognitive-behavioral health
improvement
Review BA strategies
Treatment conclusion and management of
potential obstacles
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– Significant change in depressive symptoms on the
Hamilton Depression Rating Scale (HDRS) from
baseline to the end of treatment, and at 3-, 6-, and
12-month follow-up.
Secondary outcome measures
 Continuous abstinence: in accordance with the Russell
Standard [56], we will consider that participants have
achieved continuous abstinence if they report not
having smoked more than five cigarettes from the start
of the abstinence period, and have an expired carbon
monoxide reading of ≤10 ppm.
 Reduction of cigarette consumption by 50% or more
between baseline and each follow-up will be calculated
by the mean number of cigarettes smoked at the end
of treatment and in the 7 days prior to the 3-month
follow-up. At 6-, and 12-month follow-ups, it will be
calculated by the mean number of cigarettes smoked
in the past 30 days.
 Significant change in the Environmental Reward
Observation Scale (EROS) scores from baseline to the
end of treatment, and at 3-, 6-, and 12-month follow-up.
 Significant change in the Behavioral Activation for
Depression Scale (BADS) scores from baseline to the
end of treatment, and at 3-, 6-, and 12-month follow-up.
Data management and confidentiality
Data will be collected from participants both in paper
and electronic format. To make anonymization possible,
a unique identity code number for use on trial docu-
ments and electronic database will be assigned to each
participant. Data collected on paper forms will be kept
in a locked filing cabinet. Electronic data will be kept in
password-protected computer folders at the Smoking
Cessation and Addictive Disorders Unit (University of
Santiago de Compostela). Only authorized trial staff will
have access to trial documentation.
Ethical principles
The Bioethics Committee of the University of Santiago
de Compostela approved this study, which is registered
with the international standard randomized controlled
trial number NCT02844595 (www.clinicaltrials.gov). The
participants will be provided with both oral and written
information regarding the study prior to obtaining their
informed consent.
Statistical analysis
All data analysis will follow the intention-to-treat principle.
This conservative approach aims to minimize selection bias
through the inclusion in the primary analysis of data from
all the participants randomized to each group, including
those who drop out of the study.
We will conduct descriptive analysis to summarize the
characteristics of the total sample, and the characteristics of
the participants in each of the three groups. The main ana-
lysis will be a comparison between both active groups and
the control group of the proportions of abstinent smokers
at the end of treatment, and between BA intervention
group and standard intervention group at the end of treat-
ment, and at 3-, 6-, and 12-month follow-ups, through chi-
square tests and odds ratios with 95% confidence intervals.
A t-test analyses will be conducted to determine whether
there were any significant differences between the two
active treatment groups and the control group in continu-
ous variables such as BDI-II score. We also will conduct
mediation analysis, multiple regression analysis, repeated
measures ANOVA, and survival analysis.
The study results will be reported in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
2010 statements [58, 59] and Standard Protocol Item: Rec-
ommendations for Interventional Trials (SPIRIT) guide-
lines [60, 61].
Discussion
To our knowledge, this is the first randomized con-
trolled trial conducted evaluating the efficacy of a
cognitive-behavioral smoking cessation intervention
(CBSCI) with components of Behavioral Activation (BA).
As the relationship between depressive symptoms, even
at subclinical levels, and difficulties in abstinence
achievement and maintenance is well known, we expect
that this intervention will allow obtaining higher abstin-
ence rates, lower relapse rates, and mood improvement
after the treatment and at long-term.
This study has significant strengths: (1) to date, it will be
the largest trial to address the clinical-effectiveness of BA
integrated into a cognitive-behavioral smoking cessation
treatment; (2) follow-up assessments will be carried out at
3-, 6- and 12-month post-treatment in both active groups
(CBSCI vs. CBSCI + BA), which will provide an opportun-
ity to evaluate the long-term treatment effects on abstin-
ence rates and mood; and (3) participants will be included
regardless of current depressive symptom level, which will
allow us to investigate the influence of subclinical depres-
sive symptomatology in treatment outcomes.
We expect to find that an effective, brief, and flexible
intervention for depression such as BA could be imple-
mented as a part of a cognitive-behavioral treatment for
smoking cessation in order to improve its efficacy. The
findings obtained will have significant clinical implications.
Because of the relevance of depressive symptoms in the
smoking cessation process, this intervention could be a
good option to address two problems that have a very high
impact on people’s health and quality of life.
Becoña et al. BMC Psychiatry  (2017) 17:134 Page 8 of 10
Trial status
The study started in January 2016, and the recruitment
is ongoing.
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